Genetic testing in a cohort of young patients with HER2 amplified breast cancer
Genetic testing in a cohort of young patients with HER2 amplified breast cancer
Introduction: Young age at diagnosis for breast cancer raises the question of genetic susceptibility. We explored breast cancer susceptibility genes testing amongst patients with HER2 amplified invasive breast cancer aged 40 years or younger.
Patients and methods: Patients were selected from a large UK cohort study and were aged ?40 at diagnosis with confirmed HER2 amplified breast cancer. The probability of finding a BRCA gene mutation was calculated based on family history. Genetic testing was either clinical testing for BRCA1 and BRCA2 with a subset also tested for TP53 mutations, or research based testing using a typical panel comprising 17 breast cancer susceptibility genes (CSGs) including BRCA1, BRCA2 and TP53.
Results: There were 591 eligible patients. Clinical testing results were available for 133 cases; an additional 263 cases had panel testing. BRCA testing across 396 cases found 8 BRCA2 (2%) and 6 BRCA1 (2%) pathogenic mutations. Of 304 tested for TP53 mutations overall 9 (3%) had deleterious TP53 mutations.
Of 396 patients, 101 (26%) met clinical criteria for BRCA testing (?10% probability), amongst whom BRCA testing yielded 11% with pathogenic BRCA mutations (6 BRCA2, 5 BRCA1). Where the probability was calculated to be <10%, only 4/295 (1%) had BRCA mutations. Amongst the 59 patients meeting the 10% threshold who had TP53 testing, there were 7 mutations (12%). Likely functionally deleterious mutations in 14 lower penetrance CSGs were present in 12/263(5%) panel tested patients.
Conclusion: Patients under 41 at diagnosis with HER2+ breast cancer and no family history of breast cancer can be reassured that they have a low chance of being a high risk gene carrier. If there is a strong family history, not only BRCA but also TP53 gene testing should be considered. The clinical utility of testing lower penetrance CSGs remains unclear.
HER2 positive, breast cancer, young onset, genetic testing, gene panel
467-73
Eccles, D.M.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Li, N.
f3f8b4ff-900b-4f1f-b6dc-ac4d884ba1bb
Handwerker, R.
75d6722d-48c1-4ddc-8e7f-6132e861e979
Maishman, T.
cf4259a4-0eef-4975-9c9d-a2c3d594f989
Copson, E.R.
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Durcan, L.T.
bd059b41-9e77-4afe-b271-9ac4c91a05c6
Gerty, S.M.
b2013815-27c9-4a7d-ad42-071f60a8000f
Jones, L.
b873ef7a-7df0-4411-9287-b35c45663770
Evans, D.G.
b58c99fc-4da0-4d7e-b140-f22307befe5e
Haywood, L.
0a17426c-f1c1-4eff-bb1b-262d3bf64c73
Campbell, I.
e6743f56-fcae-4a90-8182-b1cdd39362d0
March 2016
Eccles, D.M.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Li, N.
f3f8b4ff-900b-4f1f-b6dc-ac4d884ba1bb
Handwerker, R.
75d6722d-48c1-4ddc-8e7f-6132e861e979
Maishman, T.
cf4259a4-0eef-4975-9c9d-a2c3d594f989
Copson, E.R.
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Durcan, L.T.
bd059b41-9e77-4afe-b271-9ac4c91a05c6
Gerty, S.M.
b2013815-27c9-4a7d-ad42-071f60a8000f
Jones, L.
b873ef7a-7df0-4411-9287-b35c45663770
Evans, D.G.
b58c99fc-4da0-4d7e-b140-f22307befe5e
Haywood, L.
0a17426c-f1c1-4eff-bb1b-262d3bf64c73
Campbell, I.
e6743f56-fcae-4a90-8182-b1cdd39362d0
Eccles, D.M., Li, N., Handwerker, R., Maishman, T., Copson, E.R., Durcan, L.T., Gerty, S.M., Jones, L., Evans, D.G., Haywood, L. and Campbell, I.
(2016)
Genetic testing in a cohort of young patients with HER2 amplified breast cancer.
Annals of Oncology, 27 (3), .
(doi:10.1093/annonc/mdv592).
Abstract
Introduction: Young age at diagnosis for breast cancer raises the question of genetic susceptibility. We explored breast cancer susceptibility genes testing amongst patients with HER2 amplified invasive breast cancer aged 40 years or younger.
Patients and methods: Patients were selected from a large UK cohort study and were aged ?40 at diagnosis with confirmed HER2 amplified breast cancer. The probability of finding a BRCA gene mutation was calculated based on family history. Genetic testing was either clinical testing for BRCA1 and BRCA2 with a subset also tested for TP53 mutations, or research based testing using a typical panel comprising 17 breast cancer susceptibility genes (CSGs) including BRCA1, BRCA2 and TP53.
Results: There were 591 eligible patients. Clinical testing results were available for 133 cases; an additional 263 cases had panel testing. BRCA testing across 396 cases found 8 BRCA2 (2%) and 6 BRCA1 (2%) pathogenic mutations. Of 304 tested for TP53 mutations overall 9 (3%) had deleterious TP53 mutations.
Of 396 patients, 101 (26%) met clinical criteria for BRCA testing (?10% probability), amongst whom BRCA testing yielded 11% with pathogenic BRCA mutations (6 BRCA2, 5 BRCA1). Where the probability was calculated to be <10%, only 4/295 (1%) had BRCA mutations. Amongst the 59 patients meeting the 10% threshold who had TP53 testing, there were 7 mutations (12%). Likely functionally deleterious mutations in 14 lower penetrance CSGs were present in 12/263(5%) panel tested patients.
Conclusion: Patients under 41 at diagnosis with HER2+ breast cancer and no family history of breast cancer can be reassured that they have a low chance of being a high risk gene carrier. If there is a strong family history, not only BRCA but also TP53 gene testing should be considered. The clinical utility of testing lower penetrance CSGs remains unclear.
Text
HER2+ Descriptive Paper final accepted.docx
- Accepted Manuscript
More information
Accepted/In Press date: 20 November 2015
e-pub ahead of print date: 17 December 2015
Published date: March 2016
Keywords:
HER2 positive, breast cancer, young onset, genetic testing, gene panel
Organisations:
Cancer Sciences, Clinical Trials Unit
Identifiers
Local EPrints ID: 384298
URI: http://eprints.soton.ac.uk/id/eprint/384298
ISSN: 1569-8041
PURE UUID: 3aaf51e0-f344-4f04-8aca-d7a1a9d6c074
Catalogue record
Date deposited: 24 Nov 2015 14:35
Last modified: 15 Mar 2024 02:40
Export record
Altmetrics
Contributors
Author:
N. Li
Author:
R. Handwerker
Author:
T. Maishman
Author:
L.T. Durcan
Author:
S.M. Gerty
Author:
L. Jones
Author:
D.G. Evans
Author:
L. Haywood
Author:
I. Campbell
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
